Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-C477 in Advanced Solid Tumors
NCT06596473Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Oct 2024
- Primary completion
- Jul 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 8
01
Overview
Phase 1, open-label trial of BG-C477 in solid tumor (4 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) at 1 year and 3 more. Started Oct 2024; status: recruiting.
02
Drugs
BG-C477
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06596473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06596473.